Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Nov 21, 2019
Amgen Completes Acquisition Of Otezla® (apremilast)
Aug 26, 2019
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Aug 05, 2019
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
Jul 18, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
Jul 10, 2019
TARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (nivolumab) for Patients with Muscle-Invasive Bladder Cancer
Apr 30, 2019
The World Market for Esophageal Cancer - Forecast to 2023 with Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co, and Sanofi Dominating
Jan 07, 2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
Jan 03, 2019
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of Celgene Corporation; Are Celgene Shareholders Getting a Fair Deal?
Nov 05, 2018
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Oct 11, 2018
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Apr 16, 2018
Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Apr 03, 2018
Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb
Mar 13, 2018
GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights
Mar 12, 2018
Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors
Nov 16, 2017
Guardant Health Expands Support for the Development of the GuardantOMNI(TM) Assay Through New Agreement with Bristol-Myers Squibb
Sep 22, 2017
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Jun 03, 2017
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
May 30, 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration